Smith v. DG Louisiana, LLC

CourtDistrict Court, M.D. Louisiana
DecidedNovember 4, 2020
Docket3:19-cv-00360
StatusUnknown

This text of Smith v. DG Louisiana, LLC (Smith v. DG Louisiana, LLC) is published on Counsel Stack Legal Research, covering District Court, M.D. Louisiana primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smith v. DG Louisiana, LLC, (M.D. La. 2020).

Opinion

UNITED STATES DISTRICT COURT

MIDDLE DISTRICT OF LOUISIANA

STEPHANIE SMITH, ET AL. CIVIL ACTION VERSUS NO. 3:19-CV-360-JWD-RLB DG LOUISIANA, LLC, ET AL.

RULING ON MOTION TO EXCLUDE TESTIMONY AND OTHER EVIDENCE PERTAINING TO THE FUTURE TREATMENT RECOMMENDATIONS ATTRIBUTED TO DR. JAFFARZAD, DR. GRAHAM AND DR. ACOSTA IN THE LIFE CARE PLAN PREPARED BY AARON WOLFSON, PH.D.

Before the Court is the Motion to Exclude Testimony and Other Evidence Pertaining to the Future Treatment Recommendations Attributed to Dr. Jaffarzad, Dr. Graham, and Dr. Acosta in the Life Care Plan Prepared by Aaron Wolfson, Ph.D. (“Motion”) (Doc. 23) made by defendant DG Louisiana, LLC (“Defendant” or “DG”). It is opposed by plaintiffs Stephanie Smith (“S. Smith” or “Plaintiff”) and Dwayne Smith (collectively, “Plaintiffs”). (Doc. 26.) Defendant filed a reply. (Doc. 29.) For the following reasons, the Motion is denied. I. BACKGROUND AND ARGUMENTS OF THE PARTIES This matter arises from a slip and fall accident which occurred at a Dollar General store on March 25, 2018. (Doc. 23-1 at 2.) S. Smith claims she suffered injuries in the fall. (Id.) Plaintiffs hired Aaron Wolfson, Ph.D. (“Wolfson”) to develop a life care plan. (See Doc. 23-2.) In connection with his work preparing a life care plan, Wolfson met with four of S. Smith’s treating physicians: Dr. Jorge Isaza (“Isaza”), Dr. Sean Graham (“Graham”), Dr. Nina Jaffarzad (“Jaffarzad”) and Dr. Joseph Acosta (“Acosta”). (Id. at –6.) In his report, Wolfson lists future medical treatment he represents was recommended by one or more of these four doctors along with the frequency, duration and cost of the treatment. (Id. at 6–10.) Defendant argues that three of the physicians (Jaffarzad, Graham and Acosta) have testified that the identified future treatment recommendations contained in Wolfson’s Life Care Plan are more probably than not unrelated to the subject incident – and in some cases not even recommended. Thus, Wolfson should be barred from offering any testimony [related to certain specific treatments][,] and plaintiff should be barred from introducing other evidence pertaining to these recommendations as they are irrelevant to the subject litigation and must be excluded. (Doc. 23-1 at 1–2; see also id. at 3, 9.) In support of its contention, DG points to deposition excerpts from Jaffarzad, Graham and Acosta which it contends contradicts Wolfson’s recommendations as to certain specific treatments. (See id. at 2–7.) Specifically, DG points to testimony from Jaffarzad in which she testifies that her treatment of Plaintiff would have been the same even had Plaintiff not had the fall (id. at 3–4) and that some of the treatment Wolfson has her recommending is not treatment she would recommend “at this time” (id. at 4). DG also quotes testimony from Graham (id. at 6–7) and Acosta (id. at 5–6) to the same effect. Finally, DG directs the Court’s attention to testimony from Acosta that some items Wolfson states Acosta recommended were not recommended by him. (Id. at 5–6.) In response, Plaintiffs argue that “each and every recommendation cited within the Life Care Plan . . . was based upon [Wolfson’s] direct communication with each and every medical provider.” (Doc. 26 at 1.) In addition, following the consultation Wolfson had with each medical provider at issue, Wolfson sent each a letter giving the providers a chance to change any of their proposed recommendations. (Id.) Further, the recommendations that made were, based on his consultations with providers, were for future medical expenses “resulting from” the subject accident. (Id. at 2.) Plaintiffs maintain that, although S. Smith had preexisting conditions, these were exacerbated by the accident. (Id. at 3.) Plaintiffs note that some of the future expenses challenged by Defendant were recommended by Isaza. (Id. at 5.) Therefore, as to those recommendations, Wolfson’s opinion remains supported and should not be stricken. (Id. at 4–5.) As to Acosta, Plaintiffs claim that his testimony is, at worst, equivocal on the issue of causation and therefore the issue should be presented to and decided by the jury. (Id. at 5–6.) Plaintiffs emphasize Graham testified that Plaintiff’s herniated disc at L3-L4 level was exacerbated by the

accident and the L4 fracture was caused by the accident. (Id. at 8.) In its reply, Defendant argues that because three doctors testified that “certain future treatment” contained in the Life Care Plan was either not recommended or was unrelated to the subject accident, the recommended treatments are irrelevant to the issues in the case.” (Doc. 29 at 1–2.) Defendant repeats the arguments and supporting testimony given in its original brief and maintains that allowing Wolfson’s testimony would merely confuse the jury. (Id. at 2–3.) II. STANDARD Defendant’s motion is a Daubert challenge. See Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (1993). When Daubert is invoked, a district court may, but is not required to, hold a hearing at which the proffered opinion may be challenged. Carlson v. Bioremedi Therapeutic

Sys., Inc., 822 F.3d 194, 201 (5th Cir. 2016). However, when no hearing is held, “a district court must still perform its gatekeeping function by performing some type of Daubert inquiry.” Id. “At a minimum, a district court must create a record of its Daubert inquiry and ‘articulate its basis for admitting expert testimony.’” Id. (quoting Rodriguez v. Riddell Sports, Inc., 242 F.3d 567, 581 (5th Cir. 2001)). Pursuant to Federal Rule of Evidence 702, “a witness who is qualified as an expert by knowledge, skill, experience, training, or education may testify in the form of an opinion or otherwise” if the rule’s preconditions are met. The role of the trial court is to serve as the gatekeeper for expert testimony by making the determination of whether the expert opinion is sufficiently reliable. As the Fifth Circuit has held: [W]hen expert testimony is offered, the trial judge must perform a screening function to ensure that the expert’s opinion is reliable and relevant to the facts at issue in the case. Daubert went on to make “general observations” intended to guide a district court’s evaluation of scientific evidence. The nonexclusive list includes “whether [a theory or technique] can be (and has been) tested,” whether it “has been subjected to peer review and publication,” the “known or potential rate of error,” and the “existence and maintenance of standards controlling the technique's operation,” as well as “general acceptance.” The [Supreme] Court summarized: The inquiry envisioned by Rule 702 is, we emphasize, a flexible one. Its overarching subject is the scientific validity and thus the evidentiary relevance and reliability-of the principles that underlie a proposed submission. The focus, of course, must be solely on principles and methodology, not on the conclusions that they generate.

Watkins v. Telsmith, Inc., 121 F.3d 984, 988-89 (5th Cir. 1997) (internal citations omitted). The Supreme Court has recognized that not all expert opinion testimony can be measured by the same exact standard. Rather, the Daubert analysis is a “flexible” one, and “the factors identified in Daubert may or may not be pertinent in assessing reliability, depending on the nature of the issue, the expert’s particular expertise, and the subject of his testimony.” Kumho, 526 U.S. at 150, cited with approval in Pipitone v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Watkins v. Telsmith, Inc.
121 F.3d 984 (Fifth Circuit, 1997)
Rodriguez v. Riddell Sports, Inc.
242 F.3d 567 (Fifth Circuit, 2001)
Guy v. Crown Equipment Corp.
394 F.3d 320 (Fifth Circuit, 2004)
Rock v. Arkansas
483 U.S. 44 (Supreme Court, 1987)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Monsanto Co. v. David
516 F.3d 1009 (Federal Circuit, 2008)
Southwire Co. v. J.P. Morgan Chase & Co.
528 F. Supp. 2d 908 (W.D. Wisconsin, 2007)
CANNOM v. Elk Horn Bank and Trust
258 F. Supp. 2d 908 (W.D. Arkansas, 2002)
Carlson v. Bioremedi Therapeutic Systems, Inc.
822 F.3d 194 (Fifth Circuit, 2016)
Johnson v. Samsung Electronics America, Inc.
277 F.R.D. 161 (E.D. Louisiana, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
Smith v. DG Louisiana, LLC, Counsel Stack Legal Research, https://law.counselstack.com/opinion/smith-v-dg-louisiana-llc-lamd-2020.